Imbiologics nets $20M up front for Navigator autoimmune drug June 18, 2024 By Marian (YoonJee) Chu South Korea’s Imbiologics Inc. scored a potential $940 million (₩1.3 trillion) technology transfer deal with U.S. biotech Navigator Medicines Inc. for its bispecific antibody drug candidate, IMB-101 (Oxtima), to treat autoimmune diseases.Read More
